Programming gene and engineered-cell therapies with synthetic biology
Gene and engineered-cell therapies promise to treat diseases by genetically modifying cells to carry out therapeutic tasks. Although the field has had some success in treating monogenic disorders and hematological malignancies, current approaches are limited to overexpression of one or a few transge...
| Main Authors: | , , , |
|---|---|
| Other Authors: | |
| Format: | Article |
| Language: | en_US |
| Published: |
American Association for the Advancement of Science (AAAS)
2018
|
| Online Access: | http://hdl.handle.net/1721.1/118768 https://orcid.org/0000-0003-2265-3363 https://orcid.org/0000-0002-0302-6834 https://orcid.org/0000-0002-9833-2817 https://orcid.org/0000-0003-0396-2443 |